[go: up one dir, main page]

WO2018157863A1 - Procédé et composé pour modifier l'horloge circadienne - Google Patents

Procédé et composé pour modifier l'horloge circadienne Download PDF

Info

Publication number
WO2018157863A1
WO2018157863A1 PCT/CN2018/077909 CN2018077909W WO2018157863A1 WO 2018157863 A1 WO2018157863 A1 WO 2018157863A1 CN 2018077909 W CN2018077909 W CN 2018077909W WO 2018157863 A1 WO2018157863 A1 WO 2018157863A1
Authority
WO
WIPO (PCT)
Prior art keywords
dinaciclib
compound
composition
inhibitor
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2018/077909
Other languages
English (en)
Inventor
Tenghui YU
Yi Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peking University
Original Assignee
Peking University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peking University filed Critical Peking University
Priority to CN201880004492.8A priority Critical patent/CN109982717B/zh
Priority to US16/489,575 priority patent/US20200009134A1/en
Priority to EP18761791.5A priority patent/EP3589321B1/fr
Publication of WO2018157863A1 publication Critical patent/WO2018157863A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2864—Sleep disorders

Definitions

  • the present invention relates to a method, compound and composition modulating circadian rhythm.
  • the circadian clock is an intrinsic timing system driving the daily rhythm of multiple systems including the sleep/wake cycle, immune responsiveness and metabolism (Asher and Sassone-Corsi, 2015; Bass and Takahashi, 2010; Chong et al., 2012; Curtis et al., 2014; Takahashi et al., 2008) .
  • the master clock resides in the hypothalamic suprachiasmatic nucleus (SCN) , which synchronizes circadian oscillations existing in cells throughout the body (Dibner et al., 2010; Mohawk and Takahashi, 2011; Welsh et al., 2010) .
  • SCN hypothalamic suprachiasmatic nucleus
  • TTFL transcription-translational feedback loop
  • the first loop is the activation of three period genes (Per1, Per2, Per3) and two cryptochrome genes (Cry1, Cry2) by Bmal1 and Clock, while Per/Cry form a heterodimer to repress their own expression
  • Per1, Per2, Per3 the activation of three period genes
  • Cry1, Cry2 two cryptochrome genes
  • Per/Cry form a heterodimer to repress their own expression
  • the second loop is the activation of two nuclear receptor genes (Ror ⁇ / ⁇ , Rev-erb ⁇ ) by Bmal1 and Clock, while Ror ⁇ / ⁇ and Rev-erb ⁇ feedback on Bmal1 expression (Preitner et al., 2002; Sato et al., 2004; Ueda et al., 2002) .
  • Posttranslational modifications, especially phosphorylation, are important in clock regulation (Crane and Young, 2014; Gallego and Virshup, 2007; Mehra et al., 2009; Reischl and Kramer, 2011) .
  • the PER protein (s) the prototypical circadian regulators, are phosphorylated and defective PER phosphorylation causes circadian disruption (Akashi et al., 2002; Blau, 2008; Chiu et al., 2011; Chiu et al., 2008; Cyran et al., 2005; Edery et al., 1994; Eide et al., 2005; Etchegaray et al., 2009; Gallego et al., 2006; Garbe et al., 2013; Iitaka et al., 2005; Kaasik et al., 2013; Kim et al., 2007; Kivimae et al., 2008; Kloss et al.
  • hPER2 S662 was a priming site for casein kinase 1 (CK1 ) , whose gene was found to be mutated in another family of FASPS (Xu et al., 2005; Xu et al., 2007) .
  • hPER2 has multiple potential phosphorylation sites, with CKs and glycogen synthetase kinase (GSK) 3 implicated in its phosphorylation (Akashi et al., 2002; Eide et al., 2005; Hirota et al., 2010; Iitaka et al., 2005; Lowrey et al., 2000; Maier et al., 2009; Meng et al., 2008; Tsuchiya et al., 2009a; Vanselow et al., 2006; Xu et al., 2005; Xu et al., 2007) . It is likely that kinases other than CKs and GSK3 may also be involved in regulating the functions of hPER2 and other proteins involved in the circadian rhythm.
  • the invention provides methods and compositions for modulating, preferably phase shifting, circadian rhythm.
  • the invention provides a method for modulating, preferably phase shifting, circadian rhythm, comprising administering to a subject in need thereof an hPER2 phosphorylating kinase inhibitor.
  • the invention provides a compound for use in a subject in need thereof, or in the manufacture of a medicament, to treat jet lag, shift-work or age-related sleep disturbances, wherein the compound is an hPER2 phosphorylating kinase inhibitor.
  • composition comprising (a) an hPER2 phosphorylating kinase inhibitor, and (b) a different medicament for treating jet lag, shift-work or age-related sleep disturbances.
  • -the kinase is selected from: CDK5, PRKACB, PRKG1, IKBKB, TSSK2 and IKBKE;
  • -the kinase and inhibitor are selected from: (a) CDK5 and Dinaciclib , Cdk/crk inhibitor, Roscovitine or Indirubin-3’monoxime-5-sulphonic acid, 9-Cyanopaullone; (b) IKBKB and Ikk2 inhibitor iv, Ikk2 inhibitor v, Ikk2 inhibitor vi or AS602868; and (c) IKBKE and Cay105765;
  • the inhibitor is in unit dosage form, preferably enteral (e.g. oral) ;
  • the inhibitor and medicament are copackaged or coformulated, preferably in unit dosage form, preferably enteral;
  • the medicament is caffeine, melatonin, zolpidem, eszopiclone, zaleplon or triazolam;
  • the subject is a person exposed or determined to be at risk of exposure to jet lag, shift-work or age-related sleep disturbances;
  • the method further comprises the antecedent step of determining the subject is exposed or at risk of exposure to jet lag, shift-work or age-related sleep disturbances.
  • the invention provides a method of detecting a modulator of a mammalian intracellular clock comprising: (a) contacting a kinase with a compound and detecting a resultant inhibition of the kinase; and (b) contacting the mammalian clock with the compound and detecting a resultant modulation of the clock.
  • the kinase assay is in vitro or cell-based, and the clock assay is cell-or animal-based.
  • the invention provides a method of modulating circadian rhythm comprising administering to a subject in need thereof an effective amount of dinaciclib.
  • the invention provides a compound, dinaciclib, for use in a subject in need thereof, or in the manufacture of a medicament, to treat jet lag, shift-work or age-related sleep disturbances.
  • the invention provides a composition comprising dinaciclib, and a different medicament for treating jet lag, shift-work or age-related sleep disturbances.
  • -the dinaciclib is at a: (a) dosage that is subtherapeutic for cancer treatment; (b) dosage that is less than 50%, 20%or 10%of therapeutic or conventional cancer dosage; (c) dosage that is less than 1 or 2 or 5 or 10 or 20 mg/m 2 ; or (d) unit dosage form of less than 1, 2, 5, 10 or 20 mg;
  • the dinaciblib is in unit dosage form, preferably enteral (e.g. oral) ;
  • -the dinaciblib and medicament are copackaged or coformulated, preferably in unit dosage form, preferably enteral;
  • the medicament is caffeine, melatonin, zolpidem, eszopiclone, zaleplon or triazolam;
  • the subject is a person exposed or determined to be at risk of exposure to jet lag, shift-work or age-related sleep disturbances.
  • the method comprises the antecedent step of determining the subject is exposed or at risk of exposure to jet lag, shift-work or age-related sleep disturbances.
  • the invention encompasses all combination of the particular embodiments recited herein, as if each had been separately, laboriously recited.
  • Figs. 1a, 1b and 1c Effects of kinase inhibitors discovered in the chemical screen for their abilities to modify the circadian rhythm of U2OS cell.
  • CDK5 inhibitors CDK5 inhibitors.
  • the terms “a” and “an” mean one or more, the term “or” means and/or and polynucleotide sequences are understood to encompass opposite strands as well as alternative backbones described herein.
  • genuses are recited as shorthand for a recitation of all members of the genus; for example, the recitation of (C1-C3) alkyl is shorthand for a recitation of all C1-C3 alkyls: methyl, ethyl and propyl, including isomers thereof.
  • dinaciclib formulations and administration are readily empirically determined or otherwise known in the art, e.g. US7,119,200; US20160193334; WO 2015130585: Unless otherwise indicated, references below to dinaciclib also include pharmaceutically acceptable salts thereof.
  • inert pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent dinaciclib.
  • Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose.
  • Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration.
  • Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed. ) , Remington 's Pharmaceutical Sciences, 18th Edition, (1990) , Mack Publishing Co., Easton, Pennsylvania.
  • Liquid form preparations of dinaciclib include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions.
  • Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations of dinaciclib suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen. Also included are solid form preparations of dinaciclib that are intended to be converted, shortly before use, to liquid form preparations of dinaciclib for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions. Dinaciclib may also be deliverable transdermally.
  • the transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose. Dinaciclib may also be delivered subcutaneously.
  • the pharmaceutical preparation can be in unit dosage form.
  • the preparation is subdivided into suitably sized unit doses containing appropriate quantities of dinaciclib, e.g., an effective amount to achieve the desired purpose.
  • the quantity of dinaciclib in a unit dose of preparation may be varied or adjusted from about 1 mg to about 100 mg, more specifically from about 1 mg to about 50 mg, more specifically from about 1 mg to about 25 mg, according to the particular application.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
  • Drugs regulating the circadian rhythm are desired to treat jet-lag, shift work-related problems and circadian-related sleep disorders in diseased or aging populations. Because the circadian clock involves protein phosphorylation, we first performed a screen for human kinases capable of phosphorylating fragments of the human Period 2 (hPER2) protein, leading to the findings of 6 kinases previously unknown for PER phosphorylation. We then performed a screen of kinase inhibitors for functional regulation of the circadian rhythm in cultured human cells.
  • hPER2 human Period 2
  • kinases for hPER2 we subcloned and cotransfected cDNAs encoding kinases with different fragments of hPER2 in HEK293T cells. 288 protein kinases were successfully tested in our system. Phosphorylation of hPER2 was detected during the screen by the phos-tag which could bind to organic phosphate in proteins to delay their migration in sodium dodecyl sulfate-polyacrylaminde gel electrophoresis (SDS-PAGE) (Kinoshita et al., 2006) .
  • SDS-PAGE sodium dodecyl sulfate-polyacrylaminde gel electrophoresis
  • the screen uncovered zero kinase phosphorylating Fragment 1-200, one kinase phosphorylating Fragment 150-400, three kinases phosphorylating Fragment 328-556 and five kinases phosphorylating Fragment 556-771. Results from the screen were validated and that the gel shift was due to phosphorylation was confirmed by phosphatase treatment.
  • IKBKB inhibitors tested here lengthened the period.
  • Three inhibitors of IKBKE showed different effects: Amelxanox and BX795 had no detectable effect whereas Cay10576 shortened the period by 0.3 h.
  • Three inhibitors of CDK5 also showed different effects.
  • dinaciclib significantly shifted the phase of the circadian rhythm of U2OS cells.
  • dinaciclib To further test the effect of dinaciclib, we used a cell line expressing Bmal1-luciferase, which oscillated in a phase different from Per2-luciferase. The phase-shifting effect of dinaciclib was confirmed in Bmal1-luciferase cells, supporting that dinaciclib affected the circadian rhythm, rather than just the expression of one reporter gene specifically. When the timing of first peak of Per2-luciferase expression was used to calculate the extent of phase shift, dinaciclib was found to delay the peak by 9.408h. When applied from the beginning of the assay, dinaciclib increased the amplitude by 1.78 fold and shortened the period by 0.6 h.
  • dinaciclib was added to Per2-luciferase expressing cells at different circadian time (CT) .
  • CT0 circadian time
  • dinaciclib was advanced by 1.7 ⁇ 0.81h if dinaciclib was introduced at CT18.
  • dinaciclib modification of the circadian rhythm is both dose-and phase-dependent.
  • U2OS cells are just cultured cells, while the SCN is the master clock in mammals.
  • SCN explants were cut into slices which maintained rhythmicity not only cell-autonomously but also in a cell-cell interaction dependent manner.
  • dinaciclib can regulate the circadian rhythm in SCN slices containing the mammalian master clock. It significantly advanced the SCN phase when applied at CT12: 00.
  • dinaciclib can modify the phase of the circadian rhythm in cultured human cells and mouse SCN explants suggests the exciting possibility that dinaciclib can be a powerful drug to treat jet lag in intact animals.
  • mice treated with a single dose of dinaciclib adapted to the new LD cycle in a significantly shorter time.
  • the 50%phase shift time (PS 50 ) for the dinaciclib-treated group was 1.34 days while that for the control was 2.63 days (p ⁇ 0.01) .
  • dinaciclib was effective in treating jet lag.
  • Dinaciclib is an anti-cancer drug with no previous evidence to indicate that it could affect the circadian rhythm (Parry et al., 2010; Paruch et al., 2010) .
  • the facts that it has passed phase I and phase II of clinical trials and that the dose used for jet lag here is lower than that for cancer treatment support the possibility that dinaciclib is relatively safe (Fabre et al., 2014; Flynn et al., 2015; Gojo et al., 2013; Gorlick et al., 2012; Hu et al., 2015; Kumar et al., 2015; Mita et al., 2014; Mitri et al., 2015; Nemunaitis et al., 2013a; Stephenson et al., 2014; Zhang et al., 2012) .
  • CDK5 could phosphorylate hPER2 Fragment 150-400.
  • CDK5 is an atypical cyclin dependent kinase which is activated by P35 or P39 instead of cyclin (Dhavan and Tsai, 2001) .
  • Fragment 150-400 contains one PAS domain, which is for the transcriptional regulatory activity of PER proteins.
  • CDK5 could phosphorylate the CLOCK protein (Kwak et al., 2013) .
  • the immune system is under the control of circadian rhythm (Curtis et al., 2014; Scheiermann et al., 2013) .
  • IKBKB and IKBKE two kinases known to be important in the immune system (Chen, 2012) , could phosphorylate hPER2 fragments.
  • IKBKB inhibitors could lengthen the period of U2OS.
  • the degradation of hPER2 requires the ubiquitination in the region 328-771 which is also phosphorylation dependent (Eide et al., 2005; Ohsaki et al., 2008) .
  • the S662G mutation found in FASPS is in this region (Toh et al., 2001) .
  • dinaciclib is the most potent and has a unique kinase selectivity profile, though it remains to be investigated which CDK is the endogenous target of dinaciclib for its modification of the circadian rhythm.
  • regulators of kinase activities can provide effective and safe modifiers of the circadian rhythm, alleviating problems associated with not only jet lag, but also shift-work and age related sleep disturbances.
  • mice were returned to the home cage under a LD cycle (light on at CT3: 00, light off at CT15: 00) for 7 days before video recording of mouse activities began.
  • CT 20: 00 Dinaciclib dissolved in 20%hydroxypropyl- ⁇ -cyclodextran (Parry et al., 2010) (at the concentration of 5mg/ml, at the speed of 0.5 l/min) or vehicle alone was pumped into the brain to achieve the total amount of 0.1 mg/kg of body weight by the UltraMicroPump III under the help of Micro4 Controller.
  • CDK5 cyclin-dependent kinase 5
  • PRKACB protein kinase cAMP-activated catalytic subunit beta
  • PRKG1 Protein kinase cGMP-dependent, Type 1
  • IKBKB also IKK2
  • IKBKE Inhibitor of nuclear factor kappa-B kinase subunit epsilon
  • TSSK2 testis specific serine kinase 2 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

Le rythme circadien est modulé par l'administration d'un inhibiteur de kinase de phosphorylation de hPER2 déphasant le rythme circadien.
PCT/CN2018/077909 2017-03-03 2018-03-02 Procédé et composé pour modifier l'horloge circadienne Ceased WO2018157863A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201880004492.8A CN109982717B (zh) 2017-03-03 2018-03-02 用于修改昼夜节律钟的方法和化合物
US16/489,575 US20200009134A1 (en) 2017-03-03 2018-03-02 Method and Compound for Modifying Circadian Clock
EP18761791.5A EP3589321B1 (fr) 2017-03-03 2018-03-02 Procédé et composé pour modifier l'horloge circadienne

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017075570 2017-03-03
CNPCT/CN2017/075570 2017-03-03

Publications (1)

Publication Number Publication Date
WO2018157863A1 true WO2018157863A1 (fr) 2018-09-07

Family

ID=63369742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/077909 Ceased WO2018157863A1 (fr) 2017-03-03 2018-03-02 Procédé et composé pour modifier l'horloge circadienne

Country Status (4)

Country Link
US (1) US20200009134A1 (fr)
EP (1) EP3589321B1 (fr)
CN (1) CN109982717B (fr)
WO (1) WO2018157863A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021164770A1 (fr) * 2020-02-21 2021-08-26 Peking University Agents et procédés de réglage du sommeil
CN112725437B (zh) * 2021-02-02 2022-12-06 暨南大学 节律基因蛋白表达和rna甲基化修饰在制备衰老检测试剂盒中的应用
CN114848795B (zh) * 2021-02-03 2023-04-14 四川大学 RORa蛋白及其激动剂在制备抗衰老药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008129069A1 (fr) * 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibiteurs des protéines kinases
WO2010011331A2 (fr) * 2008-07-24 2010-01-28 The Regents Of The University Of California Compositions et procédés se rapportant à la fonction sirt1
WO2010121225A2 (fr) * 2009-04-17 2010-10-21 Cylene Pharmaceuticals, Inc. Méthodes de traitement de troubles liés à l'activité de la protéine kinase ck2
WO2015026634A1 (fr) * 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Traitement du cancer avec une combinaison d'un antagoniste de pd-1 et du dinaciclib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146873A1 (en) * 2002-01-11 2004-07-29 Louis Ptacek Advanced sleep phase syndrome gen in humans
US20180071272A1 (en) * 2014-10-23 2018-03-15 The Trustees Of The University Of Pennsylvania Novel chronotherapy based on circadian rhythms

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008129069A1 (fr) * 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibiteurs des protéines kinases
WO2010011331A2 (fr) * 2008-07-24 2010-01-28 The Regents Of The University Of California Compositions et procédés se rapportant à la fonction sirt1
WO2010121225A2 (fr) * 2009-04-17 2010-10-21 Cylene Pharmaceuticals, Inc. Méthodes de traitement de troubles liés à l'activité de la protéine kinase ck2
WO2015026634A1 (fr) * 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Traitement du cancer avec une combinaison d'un antagoniste de pd-1 et du dinaciclib

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IANES, CHIARA ET AL.: "CKlð activity is modulated by CDK2/E- and CDK5/p35-mediated phosphorylating", AMINO ACIDS, vol. 48, 31 December 2016 (2016-12-31), pages 579 - 592, XP035889336 *
See also references of EP3589321A4 *
TOH, KONG L. ET AL.: "An hPer2 Phosphorylation Site Mutation in Familial Advanced Sleep Phase Syndrome", SCIENCE, vol. 291, 9 February 2001 (2001-02-09), pages 1040 - 1043, XP055540585 *

Also Published As

Publication number Publication date
CN109982717B (zh) 2022-07-08
EP3589321A1 (fr) 2020-01-08
EP3589321A4 (fr) 2020-07-29
EP3589321B1 (fr) 2022-10-05
US20200009134A1 (en) 2020-01-09
CN109982717A (zh) 2019-07-05

Similar Documents

Publication Publication Date Title
Huang et al. Targeting the PI3K/AKT/mTOR signaling pathway in the treatment of human diseases: current status, trends, and solutions
He et al. Targeting PI3K/Akt signal transduction for cancer therapy
JP6817287B2 (ja) キラルジアリール大環状分子及びその使用
US20220016083A1 (en) Methods of treating cancers
EP3931564A2 (fr) Procédés pour traiter des cancers positifs aux map3k8
EP2598508B1 (fr) Isoxazolo-quinazolines en tant que modulateurs de l'activité protéine kinase
US20180319795A1 (en) THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r)
JP2021001186A (ja) 黒色腫の治療のための組合せ医薬
Yin et al. Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan
BR112012022801B1 (pt) Método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
RS57838B1 (sr) Arilhinazolini
Morgan et al. Mitogen‐activated protein kinase‐activated protein kinase‐2 (MK2) and its role in cell survival, inflammatory signaling, and migration in promoting cancer
WO2018157863A1 (fr) Procédé et composé pour modifier l'horloge circadienne
CN103212064A (zh) 磷酸化途径相关因子在调控调节性t细胞功能中的应用
Dorronsoro et al. Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs?
US20230158034A1 (en) Co-treatment with cdk4/6 and cdk2 inhibitors to suppress tumor adaptation to cdk2 inhibitors
Tang et al. Novel medicinal chemistry strategies targeting CDK5 for drug discovery
Zheng et al. Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy
Hede et al. Oncoprotein stabilization in brain tumors
Park et al. Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors
CN112341436A (zh) 基于靶向抑制和降解alk的苯并咔唑类蛋白水解靶向嵌合分子、制备方法及用途
Kumar et al. Epidermal growth factor receptor and its trafficking regulation by acetylation: Implication in resistance and exploring the newer therapeutic avenues in cancer
JP2007513967A (ja) 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
Cui et al. Inhibition of RACK1‐Mediated NLRP3 Oligomerization (Active Conformation) Ameliorates Acute Respiratory Distress Syndrome
Haripriya et al. Advancements of anticancer agents by targeting the Hippo signalling pathway: biological activity, selectivity, docking analysis, and structure–activity relationship

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18761791

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2018761791

Country of ref document: EP